Current Portfolio

Kinaset

Developing inhaled therapeutics in respiratory diseases.

Key Facts

Sector: Life Sciences
Country: United States
Fund: LSP 7
Entry: 2026
Website: Kinaset

Kinaset

Responsible Partner

Daniela Begolo

Daniela Begolo

Managing Director

News

January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Kinaset | EQT Portfolio